We are live on ! Find out more
PRVB

Provention Bio, Inc. Common Stock
PRVB

Delisted

PRVB was delisted on the 26th of April, 2023.

Back to rankings

60 hedge funds and large institutions have $131M invested in Provention Bio, Inc. Common Stock in 2019 Q4 according to their latest regulatory filings, with 24 funds opening new positions, 19 increasing their positions, 12 reducing their positions, and 11 closing their positions.

New
Increased
Maintained
Reduced
Closed

211% more capital invested

Capital invested by funds: $42.2M → $131M (+$88.9M)

118% more first-time investments, than exits

New positions opened: 24 | Existing positions closed: 11

109% more call options, than puts

Call options by funds: $3.75M | Put options by funds: $1.79M

58% more repeat investments, than reductions

Existing positions increased: 19 | Existing positions reduced: 12

25% more funds holding

Funds holding: 48 → 60 (+12)

Holders
60
Holders Change
+12
Holders Change %
+25%
% of All Funds
1.18%
Holding in Top 10
1
Holding in Top 10 Change
+1
Holding in Top 10 Change %
% of All Funds
0.02%
New
24
Increased
19
Reduced
12
Closed
11
Calls
$3.75M
Puts
$1.79M
Net Calls
+$1.96M
Net Calls Change
+$2.24M

Top Buyers

Rank Fund Capital Flow
1
PA
Perceptive Advisors
New York
+$20.1M
2
BlackRock
BlackRock
New York
+$1.55M
3
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$1.41M
4
Invesco
Invesco
Georgia
+$1.36M
5
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT)
United Kingdom
+$1.33M

Top Sellers

Rank Fund Capital Flow
1
DM
Deerfield Management
New York
-$4.95M
2
SCM
Segantii Capital Management
Hong Kong
-$4.13M
3
Morgan Stanley
Morgan Stanley
New York
-$1.76M
4
MS
Maven Securities
Jersey
-$1.7M
5
MWNA
Marshall Wace North America
New York
-$1.37M
Name Holding Trade Value Shares
Change 		Change in
Stake
JGC
26
J. Goldman & Co
New York
$651K +$389K +43,660 New
RJFSA
27
Raymond James Financial Services Advisors
Florida
$640K +$103K +11,609 +37%
Lido Advisors
28
Lido Advisors
California
$579K -$8.02K -900 -2%
Millennium Management
29
Millennium Management
New York
$556K +$142K +15,989 +75%
VEA
30
Virtus ETF Advisers
New York
$523K +$313K +35,118 New
HP
31
Hound Partners
New York
$522K +$312K +35,000 New
AG
32
Advisor Group
Arizona
$484K -$754K -84,671 -72%
VF
33
Virtu Financial
New York
$401K +$240K +26,924 New
State Street
34
State Street
Massachusetts
$339K +$50.2K +5,630 +33%
UBS Group
35
UBS Group
Switzerland
$311K +$75.5K +8,470 +68%
SCP
36
Silverleafe Capital Partners
Tennessee
$298K – – –
OGC
37
One68 Global Capital
New York
$273K +$163K +18,331 New
OAM
38
Oxford Asset Management
United Kingdom
$242K +$145K +16,274 New
6CM
39
683 Capital Management
New York
$233K +$139K +15,608 New
CHAM
40
Clear Harbor Asset Management
Connecticut
$231K – – –
Squarepoint
41
Squarepoint
New York
$226K +$11.2K +1,252 +9%
MA
42
Mutual Advisors
Nebraska
$224K +$134K +15,000 New
AGM
43
Alpine Global Management
New York
$217K +$130K +14,535 New
Charles Schwab
44
Charles Schwab
California
$217K +$130K +14,553 New
BRWA
45
B. Riley Wealth Advisors
Florida
$194K +$116K +13,000 New
Morgan Stanley
46
Morgan Stanley
New York
$155K -$1.76M -197,385 -95%
TRCT
47
Tower Research Capital (TRC)
New York
$109K -$114K -12,844 -64%
Bank of America
48
Bank of America
North Carolina
$105K +$13.7K +1,532 +28%
Group One Trading
49
Group One Trading
Illinois
$103K +$26.8K +3,008 +77%
Simplex Trading
50
Simplex Trading
Illinois
$101K -$989 -111 -2%
1
2
3

PRVB Hedge Fund Activity: Q4 2019 in Review

60 of the 5,075 institutional investors tracked by Wall St. Rank reported a position in Provention Bio, Inc. Common Stock (PRVB) for Q4 2019, worth a combined $131M — up 211% from $42.2M a quarter earlier.

Buyers outnumbered sellers: 24 funds opened new PRVB positions and 11 closed out — a net gain of 13 holders — while 19 added to existing stakes and 12 trimmed.

The largest buyer was Perceptive Advisors, adding an estimated $20.1M. The largest seller was Deerfield Management, exiting entirely with an estimated $4.95M sold.

  • 60 institutional investors held Provention Bio, Inc. Common Stock (PRVB) as of Q4 2019, up from 48 in Q3 2019.
  • Funds reported $131M of Provention Bio, Inc. Common Stock stock for Q4 2019, up 211% quarter-over-quarter.
  • 24 funds opened new Provention Bio, Inc. Common Stock positions in Q4 2019 and 11 closed out, a net change of +13 holders.
  • The largest Provention Bio, Inc. Common Stock buyer in Q4 2019 was Perceptive Advisors, an estimated $20.1M added.
  • The largest Provention Bio, Inc. Common Stock seller in Q4 2019 was Deerfield Management, an estimated $4.95M sold.

Based on aggregated 13F filings for Q4 2019.